AnaptysBio, Inc. (ANAB) Stock Rating Upgraded by Zacks Investment Research

AnaptysBio, Inc. (NASDAQ:ANAB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

A number of other research analysts also recently weighed in on ANAB. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a report on Tuesday, September 12th. Royal Bank Of Canada initiated coverage on AnaptysBio in a report on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price on the stock. JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a report on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 target price on AnaptysBio and gave the stock a “buy” rating in a report on Wednesday, October 11th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $76.25.

Shares of AnaptysBio (NASDAQ ANAB) traded down $0.60 during trading hours on Friday, reaching $66.50. The company had a trading volume of 199,900 shares, compared to its average volume of 425,939. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $74.00. The company has a current ratio of 10.77, a quick ratio of 11.50 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. analysts expect that AnaptysBio will post -1.72 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/11/13/anaptysbio-inc-anab-stock-rating-upgraded-by-zacks-investment-research.html.

In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 1,951 shares in the last quarter. Bank of America Corp DE bought a new position in AnaptysBio in the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC lifted its position in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 1,000 shares in the last quarter. New York State Common Retirement Fund bought a new position in AnaptysBio in the 2nd quarter valued at approximately $168,000. Finally, Nationwide Fund Advisors lifted its position in AnaptysBio by 89.5% in the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,776 shares in the last quarter. 59.40% of the stock is currently owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply